Download PDF
Thromb Haemost 1988; 60(01): 068-074
DOI: 10.1055/s-0038-1647637
Original Article
Schattauer GmbH Stuttgart

A Monoclonal Antibody to the Human Platelet Glycoprotein II b/III a Complex Induces Platelet Activation

Piet W Modderman
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
Han G Huisman
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
Jan A van Mourik
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
Albert E G Kr von dem Borne
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 02 December 1987

Accepted after revision 07 April 1988

Publication Date:
30 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The platelet glycoprotein (GP) IIb/IIIa complex functions as the receptor for fibrinogen on activated platelets. The effects of two anti-GPIIb/IIIa monoclonal antibodies on platelet function were studied. These antibodies, 6C9 and C17, recognized different epitopes, which were exclusively present on the undissociated GPIIb/IIIa complex. Whereas C17 inhibited the binding of fibrinogen to platelets and platelet aggregation induced by adenosine diphosphate (ADP) or collagen, 6C9 caused irreversible aggregation of platelets, both in the presence and absence of extracellular fibrinogen. When incubated with unstirred (nonaggregating) platelets, 6C9 induced release of alpha and dense granule-constituents as well as binding of 125I-fibrinogen to platelets. The latter was evidently mediated in part by platelet-derived ADP, since it was inhibited to a large extent by apyrase, the ADP-hydrolyzing enzyme. F(ab’)2 fragments of 6C9 did not induce platelet-release reactions but caused (slow) aggregation of platelets in the presence of extracellular fibrinogen.

These results indicate that binding of an antibody to a specific site on the platelet GPIIb/IIIa complex may cause fibrinogen-mediated aggregation. The Fc part of the platelet-bound antibody appears to be involved in the induction of platelet release.

Key words

Platelet activation - Glycoprotein IIb/IIIa complex - Anti-GPIIb/IIIa monoclonal antibody
 

  • References

  • 1 Baumgartner HR, Muggli R. Adhesion and aggregation: morphological demonstration and quantitation in vivo and in vitro. In: Platelets in Biology and Pathology, Vol 1. Gordon JL. (ed) Elsevier/North Holland Biomedical Press; Amsterdam: 1976. pp 23-60
    Google Scholar
  • 2 Mustard JE, Packham MA, Kinlough-Rathbone RL, Perry DW, Regoeczi E. Fibrinogen and ADP-induced platelet aggregation. Blood 1978; 52: 453-466
    PubMedGoogle Scholar
  • 3 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-1401
    CrossrefPubMedGoogle Scholar
  • 4 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-5363
    PubMedGoogle Scholar
  • 5 Hawiger J, Parkinson S, Timmons S. Prostacyclin inhibits mobilization of fibrinogen binding sites on human ADP and thrombin-treated platelets. Nature 1980; 283: 195-197
    CrossrefPubMedGoogle Scholar
  • 6 Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 1980; 55: 841-847
    PubMedGoogle Scholar
  • 7 Di Minno G, Thiagarajan P, Perussia B, Martinez J, Shapiro S, Trinchieri G, Murphy S. Exposure of platelet fibrinogen-binding sites by collagen, arachidonic acid, and ADP: inhibition by a monoclonal antibody to the glycoprotein IIb-IIIa complex. Blood 1983; 61: 140-148
    PubMedGoogle Scholar
  • 8 Mustard JF, Kinlough-Rathbone RL, Packham MA, Perry DW, Harfenist EJ, Pai KR M. Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP and Chymotrypsin. Blood 1979; 54: 983-987
    PubMedGoogle Scholar
  • 9 McEver RP, Bennett EM, Martin MN. Identification of two structurally and functionally distinct sites on human platelet membrane glycoprotein Ilb-IIIa using monoclonal antibodies. J Biol Chem 1983; 258: 5269-5275
    PubMedGoogle Scholar
  • 10 Pidard D, Montgomery RR, Bennett JS, Kunicki TJ. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983; 258: 12582-12586
    PubMedGoogle Scholar
  • 11 Tetteroo PA T, Lansdorp PM, Leeksma OC, Von dem Borne Kr AE G. Monoclonal antibodies against human platelet glycoprotein IIIa. Br J Haematol 1983; 55: 509-522
    CrossrefPubMedGoogle Scholar
  • 12 Newman PJ, Allen RW, Kahn RA, Kunicki TJ. Quantitation of membrane glycoprotein IIIa on intact human platelets using the monoclonal antibody, AP-3. Blood 1985; 65: 227-232
    PubMedGoogle Scholar
  • 13 Trapani Lombardo V, Hodson E, Roberts JR, Kunicki TJ, Zimmerman TS, Ruggeri ZM. Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody. J Clin Invest 1985; 76: 1950-1958
    CrossrefPubMedGoogle Scholar
  • 14 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 15 Fraker PJ, Speck JC. Protein and cell membrane iodinations with sparingly soluble chloramide-1,2,4,6-tetrachloro-3α,6α-diphenyl glycouril. Biochem Biophys Res Commun 1980; 4: 849-857
    PubMedGoogle Scholar
  • 16 Legrand C, Dubernard V, Nurden AT. Characteristics of collagen-induced fibrinogen binding to human platelets. Biochim Biophys Acta 1985; 812: 802-810
    CrossrefPubMedGoogle Scholar
  • 17 Von dem Borne Kr AE G, Verheugt FW A, Oosterhof F, Von Riesz E, Brutel de la Rivière A, Engelfriet CP. A simple immunofluorescence test for the detection of platelet antibodies. Br J Haematol 1978; 39: 195-207
    CrossrefPubMedGoogle Scholar
  • 18 Plow EF, Byers V, Marguerie GA. The interaction of fibrinogen with its platelet receptor: a methodological approach for receptor identification and characterization. In: Measurements of Platelet Function. Harker LA, Zimmerman TS. (eds) Churchill-Livingstone; Edinburgh: 1983. pp 177-188
    Google Scholar
  • 19 Trucco M, De Petris S. Determination of equilibrium binding parameters of monoclonal antibodies specific for cell surface antigens. In: Imunological Methods. Lefkovits I, Pernis B. (eds) Academic Press, Inc; New York: 1981. ppl 26
    Google Scholar
  • 20 Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-672
    CrossrefPubMedGoogle Scholar
  • 21 Rubinow SI. A suggested method for the resolution of Scatchard plots. Immunochemistry 1977; 14: 573-576
    CrossrefPubMedGoogle Scholar
  • 22 Modderman PW, Tetteroo PA T, Leeksma OC, Bos MJ E, Van Mourik JA, Huisman JG, von dem Kr BorneA E G. Differences in functional effects of monoclonal antibodies against platelet membrane glycoproteins Ilb/IIIa. In: Monoclonal Antibodies and Human Blood Platelets. McGregor JL. (ed) Elsevier; Amsterdam: 1986. pp 131-141
    Google Scholar
  • 23 Von dem Kr BorneA E G, Modderman PW, Risseeuw-Bogaert NJ, Bos MJ E, Visser FJ, Giltay JG, Van der Schoot CE, Tetteroo PA T. Serological and biochemical studies with monoclonal antibodies against platelets. In: Leukocyte Typing III. McMichael AJ. (ed) Oxford University Press; Oxford: 1987. pp 748-755
    Google Scholar
  • 24 Pidard D, Didry D, Kunicki TJ, Nurden AT. Temperature-dependent effects of EDTA on the membrane glycoprotein IIb-IIIa complex and platelet aggregability. Blood 1986; 67: 604-611
    PubMedGoogle Scholar
  • 25 Toleffson DM, Majerus PW. Inhibition of human platelet aggregation by monovalent anti-fibrinogen antibody fragments. J Clin Invest 1975; 55: 1259-1268
    CrossrefPubMedGoogle Scholar
  • 26 Bennett JS, Hoxie JA, Leitman SF, Vilaire G, Cines DB. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci USA 1983; 80: 2417-2421
    CrossrefPubMedGoogle Scholar
  • 27 Plow EF, Marguerie GA. Participation of ADP in the binding of fibrinogen to thrombin-stimulated platelets. Blood 1980; 56: 553-555
    PubMedGoogle Scholar
  • 28 Peerschke EI B. The platelet fibrinogen receptor. Semin Hematol 1985; 22: 241-259
    PubMedGoogle Scholar
  • 29 Moncada S, Vane JR. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull 1978; 34: 129-135
    CrossrefPubMedGoogle Scholar
  • 30 Lam SC-T, Forsyth J, Piersbacher MD, Ruoslahti E, Plow EF, Ginsberg MH. A synthetic peptide containing a fibronectin cell attachment sequence inhibits platelet aggregation and binds specifically and saturably to platelets. Fed Proc 1985; 44: 1126 (abstr)
    PubMedGoogle Scholar
  • 31 Coller BS. Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol 1986; 103: 451-456
    CrossrefPubMedGoogle Scholar
  • 32 Pfueller SL. Immunology of the platelet surface. In: Platelet Membrane Glycoproteins. George JN, Nurden AT, Phillips DR. (eds) Plenum Press; New York: 1985. pp 327-355
    Google Scholar
  • 33 De Gaetano G, Vermylen J, Verstraete M. Platelet aggregation by a specific human immunoglobulin preparation. Thromb Diath Haemorrh 1970; 24: 419-431
    PubMedGoogle Scholar
  • 34 Tobelem G, Levy-Toledano S, Nurden AT, Degos L, Caen JP. Further studies on a specific platelet antibody found in Bernard-Soulier syndrome and its effects of normal platelet function. Br J Haematol 1979; 41: 427-436
    CrossrefPubMedGoogle Scholar
  • 35 Colman RW, Schreiber AD. Effect of heterologous antibody on human platelets. Blood 1976; 48: 119-131
    PubMedGoogle Scholar
  • 36 Boucheix C, Soria C, Mirshahi M, Soria J, Perrozzz JY, Fournier N, Billard M, Rosenfeld C. Characteristics of platelet aggregation induced by the monoclonal antibody ALB6 (acute lymphoblastic leukemic antigen p24). FEBS Lett 1983; 161: 289-295
    CrossrefPubMedGoogle Scholar
  • 37 Brown JE, White JG, Hockett RD, Hagert KR, Kersey JH. Functional studies of p24: platelet aggregation inhibition by Fab monomers of BA-2. In: Leukocyte Typing II, Vol 2 Human B Lymphocytes. Reinherz EL, Haynes BF, Nadler LM, Bernstein ID. (eds) Springer Verlag; New York: 1986. pp 541-550
    Google Scholar
  • 38 Higashihara M, Maeda H, Shibata Y, Kume S, Ohashi T. A monoclonal anti-human platelet antibody: a new platelet aggregating substance. Blood 1985; 65: 382-391
    PubMedGoogle Scholar
  • 39 Miller JL, Kupinsky JM, Hustad KO. Characterization of a platelet membrane protein of low molecular weight associated with platelet activation following binding by monoclonal antibody AG-1. Blood 1986; 68: 743-751
    PubMedGoogle Scholar
  • 40 Jennings LK, Phillips DR, Walter WS. Monoclonal antibodies to human platelet glycoprotein IIbβ that initiate distinct platelet responses. Blood 1985; 6: 1112-1119
    PubMedGoogle Scholar
  • 41 Banga HS, Simons ER, Brass LF, Rittenhouse SE. Activation of phospholipases A and C in human platelets exposed to epinephrine: role of glycoproteins IIb/IIIa and dual role of epinephrine. Proc Natl Acad Sci USA 1986; 83: 9197-9201
    CrossrefPubMedGoogle Scholar